secwatch.observer — SEC 8-K summary
======================================

Issuer:     Opus Genetics, Inc. (IRD)
CIK:        0001228627
Form:       8-K
Filed at:   2026-06-16T20:11:35+00:00
Accession:  0001140361-26-025440
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Opus Genetics details five IRD gene therapy programs; four data readouts expected in 2027, cash runway to 2029
--------------------------------------------------------------------------------

- OPGx-RDH12 enters clinical testing in Q4 2026; OPGx-MERTK Q1 2027; OPGx-RHO H2 2027.
- OPGx-LCA5 Phase 3 dosing expected Q4 2026; OPGx-BEST1 topline data from Cohort 1 due September 2026.
- Four clinical data readouts from across the pipeline expected in 2027.
- Cash runway into 2029 expected to fund multiple clinical inflection points and potential product approvals.
- Global IRD prevalence estimates provided: RDH12 ~30,900, MERTK ~21,960, RHO ~30,200, LCA5 ~3,240, BEST1 ~21,800 patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1228627/000114036126025440/0001140361-26-025440-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1228627/000114036126025440/ef20076319_form8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-025440

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer